Apolipoprotein E Deficiency Attenuates Neuroinflammatory Responses and Demyelination in Experimental Autoimmune...

The precise etiology of multiple sclerosis (MS) remains incompletely understood, despite a well-established genetic predisposition. Clinical and epidemiological studies have identified an association between apolipoprotein E (ApoE) and MS progression; however, the underlying mechanisms remain largely unresolved. In this study, we investigated the role of ApoE in MS progression using an experimental autoimmune encephalomyelitis (EAE) model in ApoE knockout mice. EAE was induced in female C57BL/6 wild-type (WT) and ApoE knockout (ApoE KO) mice via immunization with myelin oligodendrocyte glycoprotein peptide (MOG_35-55). Neurological deficit was assessed daily by clinical scoring from day 0 to day 28 post-immunization. On days 21 and 28 post-induction, spinal cord myelin density and ultrastructure were evaluated, and mRNA expression of myelin-related genes was quantified. In parallel, microglial activation was assessed through morphological analysis, along with quantification of inflammatory marker mRNA and protein levels. Compared with the WT-EAE group, ApoE KO-EAE mice exhibited significantly reduced neurological deficit scores during the peak phase of EAE, accompanied by attenuated demyelination and upregulation of proteolipid protein 1 (PLP1). Furthermore, the number of activated Iba-1⁺ myeloid cells was markedly decreased, with correspondingly blunted morphological transformation, and both mRNA and protein levels of pro-inflammatory cytokines in Iba-1⁺ myeloid cells were significantly downregulated. Collectively, ApoE deficiency alleviated Iba-1⁺ myeloid cells activation and neuroinflammation in EAE, mitigated demyelinating lesions, and improved neurological outcomes. These findings suggest that ApoE may contribute to MS progression, at least in part, by modulating Iba-1⁺ myeloid cells-mediated inflammatory responses.